Eric C. Burton, M.D.
Dr. Burton is a neuro-oncologist who provides care for adults with primary brain tumors. His particular research interest is in determining the optimal treatment for older patients with primary brain tumors. As a new member of NOB, he hopes to apply his extensive prior neuro-oncology experience in the development of research projects that utilize population-based data analysis to answer difficult clinical questions, as well as the development of clinical trials in various sub-populations, such as geriatric patients.
As Dr. Burton launches his research program at NOB, the overarching goal is to provide the best possible care to all brain tumor patients while also determining the best regimen for each individual, keeping in mind their cognitive, functional and physiological limitations due to the disease.
1) neuro-oncology, 2) brain tumors, 3) clinical trials, 4) geriatric oncology, 5) glioblastoma
After having worked with brain tumor patients that originated from underprivileged and under-served areas, Dr. Burton’s clinical interests have expanded into determining the various factors that contribute to varying patient responses to therapy, with a specific focus on older populations. Utilizing the resources and extensive collaborative opportunities at NIH, Dr. Burton hopes to build a research program focused on determining the best clinical care regimen for brain tumor patients by utilizing both biologic and physiologic differences between patients.
Selected Key Publications
Failure to complete standard radiation therapy in glioblastoma patients: patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients..Journal of Geriatric Oncology. 19: 2019. [ Journal Article ]
The Impact of Timing of Adjuvant Therapy on Survival for Patients with Glioblastoma: An analysis of the National Cancer Database..Journal of Clinical Neuroscience. 66: 92-99, 2019. [ Journal Article ]
Survival in elderly patients with glioblastoma in the USA: A comparison of bevacizumab-based and non-bevacizumab-based regimens.Neuro-Oncology Practice. [ Journal Article ]
Survival Impact of Prolonged Radiation Therapy for Patients with Glioblastoma Treated with Combined-Modality Therapy.Neuro-Oncology Practice. [ Journal Article ]
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients Over 70 Years Old with Newly Diagnosed Glioblastoma.Oncology. 95(1): 95(1), 2018. [ Journal Article ]
Dr. Burton received both his Bachelor of Science (B.S.) and Doctor of Medicine (M.D.) degrees from University of Michigan in Ann Arbor. Following medical school, he decided to pursue a residency in Neurology at University of Chicago. Later, looking to combine his neurology training with cancer care, he pursued a Neuro-Oncology Fellowship at University of California – San Francisco (UCSF). He served as a faculty member at both University of California – Los Angeles (UCLA) and UCSF before joining the University of Louisville’s Brown Cancer Center for a number of years, eventually becoming Director of Neuro-Oncology. He began his tenure at the Neuro-Oncology Branch at NIH in early 2019 and hopes to continue serving patients in his clinical capacity in addition to developing clinical trials for select populations of brain tumor patients.
Honors, Awards and Leadership
- Top Doctor, University of Louisville - 2017, 2018
- Robert Magnin Newman Fellowship Award (UCSF)
- M.D. with Distinction, University of Michigan – Ann Arbor
Select Societies and Initiatives
- Society for Neuro-oncology
- American Society for Clinical Oncology
- American Academy of Neurology